| Literature DB >> 28321301 |
Shefali Parikh1, Justin Ratnasingham1.
Abstract
"Early Aspirin" or a medium dose of aspirin 6 hours after Coronary Artery Bypass Graft (CABG) Surgery is strongly recommend by international guidelines (EACTS 2007/AHA 2011 guidelines, Level1a evidence) to protect venous graft patency. However, compliance with Early Aspirin prescription at our centre is poor due to long standing hospital cultural practices and lack of awareness. We completed a two-cycled retrospective audit of 53 (September 2015 Baseline), 65 (January 2016 First Cycle) and 58 (June 2016 Second Cycle) consecutive CABG patients. Interval interventions included educational presentations, educational leaflets/posters, pharmacy liaison and modifications to e-prescription order-sets. Medical, nursing and pharmacy staff were involved in the audit strategies. Early aspirin prescription improved from 23% to 48% to 55% while administration of Early Aspirin improved from 17% to 38% and finally to 48% by second improvement cycle. Significantly, the proportion of patients with omission of early aspirin despite a clear clinical indication, decreased by 50% over the audit period. Important practical considerations were the last dose of anti-platelets preoperatively and amount of of bleeding from mediastinal drains post operatively. A multidisciplinary team based approach led to a 139% improvement in prescription and 182% improvement in administration of "Early Aspirin" after CABG surgery.Entities:
Year: 2017 PMID: 28321301 PMCID: PMC5348588 DOI: 10.1136/bmjquality.u211402.w6306
Source DB: PubMed Journal: BMJ Qual Improv Rep ISSN: 2050-1315
Figure 1The prescription of Early Aspirin dramatically improved from 23% to 48% and finally to 55% by the second cycle. The administration of loading dose of 300mg aspirin (Early Aspirin and delayed aspirin up to 12 hours post operatively) also showed improved trends from 17% (Baseline) to 38% (Cycle 1) and finally to 48% (Cycle 2)
Figure 2The size of each pie chart represents the proportion of patients in whom Early Aspirin was NOT GIVEN/OMITTED in each Cycle (83%,62% and 58% respectively). These patients are further divided into the Red Zone (no clinical reason for omission) and Green Zone (acceptable clinic reason for omission). The proportion of patients in the Red Zone decreased from 66% (35/53) patients, to 45% (29/65) patients to 33% (19/58) patients at baseline, Cycle 1 and Cycle 2 respectively.
Figure 3Detailed tabulated results
Figure 4Run chart